November 16, 2014 Weighing the Week Ahead: Time to Buy Commodities? …..Other Advice Here is our collection of great investor advice for this week: Stock ideas! The very hot biotech sector has pulled back a bit. (For traders, Felix actually has it as one of the few sectors that is not worth a “fresh money†buy[…]
Category: Publicity
Five Prime: A Prime Play on Proteins (9-22-14)
September 22, 2014 Five Prime: A Prime Play on Proteins By: John McCamant Following a recent meeting with top management at this firm, John McCamant—editor of The Medical Technology Stock Letter—has issued a buy recommendation for the early-stage biotech, noting that it could become a leader in immuno-oncology. Steven Halpern: Our guest today is John McCamant, the[…]
The Life Sciences Report (6-19-14)
June 19, 2014 Fire Up the Immuno-Oncology Powerhouses: by : Editors, The Life Sciences Report Forecasting when we’ll have a cure for cancer remains beyond the predictive powers of researchers and investors. But forecasting the focus of the latest American Society of Clinical Oncology meeting was in the cards: Immuno-oncology took center stage. In this[…]
Dick Davis Investment Digest (1-22-14)
January 22, 2014 Top Picks for 2014 Written By Nancy Zambell Welcome to the Dick Davis Investment Digest Top Picks for 2014. When we asked our contributors for their 2013 Top Picks, the Dow Jones Industrial Average had just closed out 2012 at 13,104.10. By the beginning of 2013, the DJIA was trading at 16,576.66—a[…]
Biotech Watchlist Update (11-6-14)
November 6, 2014 Biotech Watchlist Update: Small-Cap Biotechs Struggle to Rebound, but Investors Remain Enchanted by Big Pharma’s Solid Returns When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies haven’t yet entirely recouped[…]
U~T San Diego Isis Pharmaceuticals (9-3-14)
September 3, 2014 ISIS Heart Drugs Get Good News Drugmaker’s News Encouraging Written By Bradley J. Fikes Strengthening the outlook for its drug development pipeline, Isis Pharmaceuticals has announced progress with two of its flagship cardiovascular drugs. On Tuesday, the Carlsbad biotech presented evidence that an already-approved drug, Kynamro, dramatically reduces risk of heart attacks.[…]
Novavax Update (10-27-14)
BioInvest News for NVAX – Novavax Enters Ebola Vaccine Race with a Bang – After remaining mum during the recent Ebola hype-fest, NVAX waited until they had truly legitimate news to report. This weekend, the company released positive preclinical Ebola vaccine data in guinea pigs at the 8th Vaccine and ISV Conference in Philadelphia (10/26).[…]
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.
The Life Sciences Report (1-15-14)
January 15, 2014 The Life Sciences Report: Sound Science, Innovative Ideas and a Sprinkle of Pixie Dust by : Tracy Salcedo-Chourré 2013 was a banner year for the life sciences sector, with biotech, pharmaceutical and medtech companies buoyed by advances in therapeutic techniques, a friendly regulatory environment, lucrative partnerships and the overall market upswing. The[…]
MoneyShow Biotech Bets (11-3-14)
November 3, 2014 Biotech Bets: Cardio, Cancer, Vaccines, and Ebola Jay Silverman is a biotechnology stock analyst and an editor at the industry leading biotech newsletter, The Medical Technology Stock Letter. Here, he offers an in-depth look at three of his favorite biotech stocks. Steven Halpern: Our guest today is Jay Silverman, a biotech stock analyst with[…]
Dick Davis Investment Digest (7-23-14)
July 23, 2014 Mid-Year Top Picks for 2014 Written By Nancy Zambell Welcome to the Investment Digest Mid-Year Top Picks for 2014! This issue is our Mid-Year Top Picks Update. Many of our contributors’ recommendations returned double-digit gains so far this year. We’ve included sell recommendations on a few picks and six new Top Picks[…]
Moneyshow – Three Favorites from a Biotech Expert (3-12-14)
March 12, 2014 Three Favorites from a Biotech Expert Biotechnology analyst Jay Silverman shares his outlook for the sector and the growing trend for large drug firms to acquire successful biotech firms. The editor of The Medical Technology Stock Letter also highlights a trio of current favorites in the sector., editor of . Steve Halpern:[…]
Moneyshow – Top Pros’ Top Picks (1-6-14)
January 6, 2014 Top Pros’ Top Picks Our top stock selection for 2014 has received three Breakthrough Therapy Designations (BTD) by the FDA, and subsequent approval, in November, for Imbruvica, a very safe pill that has shown unprecedented efficacy to treat mantle cell lymphoma (MCL), suggests John McCamant, editor of The Medical Technology Stock Letter.[…]